The Overview: November 2025

Friends,

As we approach the end of the year, one thing stands out above all else: this is a moment of unprecedented opportunity to accelerate progress against ovarian and all gynecologic cancers. And thanks to you, OCRA is rising to meet that moment — driving innovation, expanding support, and providing the community that so many count on.

In 2025, OCRA invested more than $10.8 million in scientific research — part of our $14.5 million commitment this year to strengthen the community through research, patient support, education, and advocacy. From advancing early detection through AI and nanotechnology to expanding one-on-one counseling and education programs, your generosity has fueled meaningful progress.With critical conversations unfolding on Capitol Hill, OCRA is working to ensure that discoveries move forward, research remains a national priority, and patients and families are heard where it matters most. In the months ahead, new grants and global collaborations have the potential to drive more breakthroughs, and every contribution you make now helps keep that momentum strong.

As we enter the season of giving, I hope you’ll stand with us once again by making a gift toward our important year-end fundraising goal. Your impact will be doubled thanks to a generous OCRA board member who is matching all donations, dollar for dollar, up to $500,000.

Stay tuned in the coming weeks as we share more of the impact you’ve made possible — and the future we’re building together.

Warmly,

Audra Moran, President & CEO, Ovarian Cancer Research Alliance

GivingTuesday is December 2nd

A global day of generosity is almost here, and you can help launch OCRA’s year-end campaign by making an early gift or spreading the word on social media. Every show of support helps fuel hope and progress for those facing ovarian and gynecologic cancers.

OCRA’s Advocate’s Corner

With the federal government reopened under a temporary funding bill, key decisions about cancer research funding, prevention programs, and patient access still lie ahead, and state coalitions are building on strong momentum for biomarker testing legislation and other policies that directly impact our community.

OCRA’s new Center for Public Policy—including expanded policy priorities and an interactive policy map—offers powerful new tools to track legislative activity and get involved.

Learn more in OCRA’s Advocate’s Corner.

Steps 1:1 Oncology Counseling Available Over the Holidays

The holidays can be an especially difficult time to navigate a gynecologic cancer diagnosis. If you or someone you love could use extra support, OCRA’s Steps 1:1 Counseling program is here now and always.

Licensed oncology social workers provide up to 10 free counseling sessions over six months for anyone in the U.S. age 18 or older diagnosed with gynecologic cancer. Learn more.

OCRA’s Steps 1:1 Counseling and Patient Support programs are generously sponsored by Genmab, Merck, and PMV Pharma.

OCRA Board Member Laura Shawver, PhD, Recognized with Fierce 50 Award

OCRA congratulates board member Laura Shawver, PhD, who has been named a Fierce 50 Leadership Honoree for her long-standing leadership in oncology research and drug development. Shawver is also the founder of The Clearity Foundation, which joined the OCRA family in January 2025. The award was accepted on her behalf by Audra Moran, OCRA’s President and CEO, at the Fierce 50 Awards Gala. Learn more.